Adalimumab (HumiraTM): a brief review for dermatologists
Author:
- 1 January 2004
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 15 (6) , 348-352
Abstract
Adalimumab is a new purely human TNF-α monoclonal antibody that has been approved for the treatment of rheumatoid arthritis as monotherapy or in combination with methotrexate. It is administered by subcutaneous injection in a 40-mg dose every other week. The one published Phase II trial of adalimumab for psoriasis has provided very encouraging results for its efficacy. Its most important side effects relate to the development of infection while it is being used. It is a promising medication and research regarding its use continues.Keywords
This publication has 9 references indexed in Scilit:
- Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trialJournal of the American Academy of Dermatology, 2004
- Lymphoma Rates Are Low but Increased in Patients With PsoriasisArchives of Dermatology, 2003
- Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor AntagonistAnnals of Internal Medicine, 2003
- Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first‐degree relativesArthritis & Rheumatism, 2003
- Strategies for targeting tumour necrosis factor in IBDBest Practice & Research Clinical Gastroenterology, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 reviewRheumatology, 2002
- Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationAnnals of the Rheumatic Diseases, 2002
- Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?Arthritis & Rheumatism, 1998